Transformed Lymphoma

Mary Ann Anderson; Piers Blombery; John F Seymour

doi:10.1016/j.hoc.2016.07.012

Transformed Lymphoma

Hematol Oncol Clin North Am. 2016 Dec;30(6):1317-1332. doi: 10.1016/j.hoc.2016.07.012.

Authors

Mary Ann Anderson¹, Piers Blombery², John F Seymour³

Affiliations

¹ Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville 3050, Australia. Electronic address: manderson@wehi.edu.au.
² Department of Haematology, Peter MacCallum Cancer Centre, Parkville 3050, Australia.
³ Department of Haematology, Peter MacCallum Cancer Centre, Parkville 3050, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.

PMID: 27888883
DOI: 10.1016/j.hoc.2016.07.012

Abstract

Transformed lymphoma is a complex syndrome that encompasses an array of different underlying low-grade lymphoproliferative conditions transforming into more aggressive disease as manifest by morphologic, clinical, and genetic features. Over the last decade, advances in chemoimmunotherapy have led to new options. Knowledge surrounding the genetic changes driving the process of transformation is leading to novel targeted therapies. This article focuses on the transformation of chronic lymphocytic leukemia and follicular lymphoma into diffuse large B-cell lymphoma.

Keywords: Genetic drivers; Indolent lymphoma; Transformed lymphoma.

Publication types

Review

MeSH terms

Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
Lymphoma, Follicular* / pathology
Lymphoma, Follicular* / therapy
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Large B-Cell, Diffuse* / therapy